Interleukin-1 in crescentic glomerulonephritis  by Atkins, Principal discussant: Robert C.
Kidney International, Vol. 48 (1995), pp. 576—586
NEPHROLOGY FORUM
Inter!eukin-1 in crescentic glomerulonephritis
Principal discussant: ROBERT C. ATKINS
Monash Medical Centre, Victoria, Australia
Case presentation
A 17-year-old girl was referred to the Monash Medical Centre eight
years ago with hemoptysis and respiratory and renal failure. She was a
junior yachting champion, had no personal medical history or family
history of note, and she was not a smoker or drinker. She had presented
to her local doctor one month earlier with mild hemoptysis. A sputum
sample and chest radiograph were unremarkable, and she was given a
course of oral sulfamethoxazole-trimethoprim. One week later she devel-
oped night sweats, low-grade fever, weiglt loss, and epistaxis. Rigid
bronchoscopy showed mildly inflamed mucosa, and the mucosal biopsies
disclosed only nonspecific inflammation. Inhaled corticosteroid therapy
was commenced (beclomethasone dipropionate, 200 g, twice daily).
Outpatient review one week later suggested that her symptoms were
improving.
Three days later she presented to this hospital acutely ill with respira-
tory and renal failure. She described progressive dyspnea and hemoptysis
over the preceding two days and was now oliguric. Examination revealed
an acutely dyspneic, perspiring and pale young woman. Blood pressure
was 180/60 mm Hg; pulse, 120 beats/mm and regular; respiratory rate,
40/mm and labored; and temperature, 37.4°C. Her circulation was hyper-
dynamic with bounding pulses and precordial heaves. Extensive use of
accessory muscles was evident; loud coarse crepitations were present
throughout both lung fields. No other remarkable physical findings were
present.
Laboratory tests showed a pH of 7.27; PaCO2, 40mm Hg; Pa02, 34mm
Hg on supplemental oxygen by mask; bicarbonate, 19 mmol/liter; creati-
nine, 1135 mol/liter; urea, 44.5 mmol/liter; sodium, 139 mmol/liter;
potassium, 5.2 mmol/liter; hemoglobin, 5.7 g/dl; white blood cell count,
29,100/mm3; and a platelet count of 500,000/mm3. A chest radiograph
revealed widespread bilateral confluent alveolar opacities.
Support was commenced with endotracheal intubation and ventilation.
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An anti-GBM antibody level obtained urgently was positive. Anti-DNA
and anti-nuclear antibodies were negative. Transfusion of packed cells
brought her hemoglobin count to 14.4 g/dl. Plasma exchange of 4 liters/day
was begun. A peripheral arteriovenous shunt was inserted, and continuous
hemofiltration was initiated. Pulse methylprednisolone, 1 g daily, and
intravenous cyclophosphamide, 2 mg/kg/day, were commenced.
The following day, fresh pulmonary hemorrhage appeared to have
ceased, but other parameters had not improved. Gas exchange declined
progressively over the succeeding days; positive end-expiratory pressure(PEEP) ventilation was started, and she was cooled to 33°C to reduce
oxygen consumption. Cyclophosphamide was increased to 3 mg/kg/day.
Despite these additional measures, she developed progressive hypoxia and
died five days after admission.
Postmortem examination revealed dense, blood-filled lungs with little or
no aeration. The kidneys displayed a flea-bitten appearance, and a
previously unsuspected left renal-vein thrombosis was present. Microscopy
of the kidneys revealed severe crescentic glomerulonephritis involving
100% of glomeruli with linear staining for IgG consistent with anti-GBM
disease. Alveolar basement membrane showed similar deposits. Culture of
glomeruli isolated after death revealed a significant increase in interleu-
kin-i activity in supematants compared with normal controls.
Discussion
PROF. ROBERT C. ATKINS (Director of Nephrology, Monash
Medical Centre, Clayton, Victoria, Australia): The case of Good-
pasture's syndrome presented here was one of 3 patients in the
initial report demonstrating that glomeruli from patients with
crescentic glomerulonephritis produce large amounts of the pro-
inflammatory cytokine interleukin-i (IL-i) and suggesting that
IL-i is an important component of the inflammatory process in
this disease [1]. Isolated cultured glomeruli secrete bioactive IL-i
as measured by the thymocyte proliferation assay. Glomeruli from
patients with crescentic glomerulonephritis produce much larger
amounts of IL-i compared with glomeruli from cadaver allografts
or normal kidneys. The source of this marked IL-i production
appears to be the large number of macrophages in these glomer-
uli. This finding is consistent with our earlier observation that
glomerular macrophage infiltration is prominent in rapidly pro-
gressive glomerulonephritis [2]. Thus, our study [i] provided the
first definitive evidence that IL-i is involved in the progression of
human crescentic glomerulonephritis and raised the possibility
that blocking IL-i could be of therapeutic benefit in this disease.
In this Forum, I will describe the properties of IL-i and the
evidence supporting a key role for IL-i in the development and
progression of glomerulonephritis. Next, I will examine the mech-
anisms by which IL-i induces renal injury. Finally, I will explore
the therapeutic potential for blocking IL-i in cases of severe
crescentic glomerulonephritis.
Interleukin-1
Interleukin-i, one of the first cytokines to be fully character-
ized, exerts a wide array of pro-inflammatory actions [3, 4J. Two
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Fig. 1. Schematic diagram of the structure and
synthesis of IL-i molecules. IL-la and IL-iD are
synthesized as 31 kD precursor proteins. While
prolL-la remains predominantly cytoplasmic,
proiL-1/3 is cleaved at the cell surface by the
interleukin-l converting enzyme (ICE) to
release mature IL-lfi In contrast, IL-ira
contains a classic signal peptide and is secreted
via the endoplasmic/Golgi route.
distinct forms of IL-i exist, namely IL-la and IL-1f3 [5, 6]. These
two molecules share structural homology but are encoded by
separate genes. Both proteins are synthesized in a 31 kD precur-
sor form, which lacks signal peptides, and thus are not secreted via
the classic endoplasmic/Golgi route (Fig. 1). ProlL-la is not
normally secreted and remains predominantly intracellular. Cell
surface prolL-la can bind to and trigger IL-i receptors (IL-iRs)
expressed on adjacent cells. In contrast, IL-1f3 needs to be
processed to a 17.5 kD mature form before it can bind to and
trigger IL-i receptors. ProIL-113 is cleaved at the cell surface by a
serine protease, termed the interleukin-13 converting enzyme
(ICE), resulting in the secretion of mature IL-1f3 [7, 8]. The two
types of IL-iR (termed I and II) are expressed by many different
cell types; each type of IL-1R can bind both forms of IL-i [9, 10].
A third IL-i-like molecule was recently identified. Termed the
interleukin-1 receptor antagonist (IL-ira), it is structurally homol-
ogous to IL-la and IL-113, is located on the same chromosome,
and has a similar gene structure [11, 12]. The IL-ira contains a
signal peptide and is secreted and glycosylated through the
endoplasmic/Golgi route. Secreted IL-ira is a 22 kD molecule,
which competes equally with both IL-la and IL-il3 for binding to
IL-iRs. However, binding of IL-ira does not trigger signal
transduction by the IL-iR [13]. In endotoxic shock, serum IL-lB
levels rapidly increase, whereas peak IL-ira production is seen
some 12 hours later, lasts longer, and results in an approximately
100-fold higher blood concentration [14]. The latter observation
strongly suggests that the IL-ira forms part of the normal
mechanism by which the body downregulates IL-i action.
Monocytes and macrophages are the principal sources of IL-i,
but a wide variety of cell types have been shown to synthesize
IL-la and IL-l mRNA and protein. These cell types include: T-
and B-cells, neutrophils, mesangial cells, fibroblasts, smooth mus-
cle cells, glial cells, and various epithelia including renal tubules
[3,4]. Although cell surface IL-la might be functionally important
in these different cell types, the physiologic relevance of IL-1j3
expression is unclear, as only monocytes/macrophages appear to
express the ICE.
Interleukin-i has a wide variety of pro-inflammatory and im-
munologic actions, some of which are listed in Table 1. In
addition, IL-i can act synergistically with other cytokines in a
Table 1. Some of the biologic actions of IL-i
Induction of fever, hypotension, and shock
Adhesion molecule expression (ICAM-i, VCAM-i)
Cytokine production (IL-i, IL-4, IL-b, TNFa)
Growth factor production (PDGF, GM-CSF, M-CSF, G-CSF)
Chemotactic molecule production (IL-8, MCP-l, RANTES)
Co-stimulation of T-cell activation
Stimulation of B-cells via IL-4 and IL-6
Endotheial cell activation
Neutrophil priming and eosinophil degranulation
Fibroblast proliferation
Cyclooxygenase and lipoxygenase gene expression
Production of collagens and collagenases
Inhibition of IL-1R type-I gene expression
range of functions. In particular, tumor necrosis factor-a (TNFa)
is both induced by IL-i and acts with IL-i in many pro-inflam-
matory actions, at least in vitro. Given the realization that
glomerulonephritis is an immunologically mediated disease in
which maerophages and T-cells play a crucial role [15], there has
been much interest in the potential role of IL-i in this disease.
Pathogenetic role of IL-i
To demonstrate a pathologic role for IL-i in the initiation and
progression of glomerulonephritis, four criteria must be fulfilled.
First, does IL-i induce responses in renal cells in vitro similar to
those observed in disease? Second, is IL-i produced within the
kidney during disease? Third, can administration of IL-i induce
renal injury or exacerbate existing disease? And fourth, does
blocking of endogenous IL-i suppress disease?
Effects of IL-i on renal cell types in vitro. The first indication that
IL-i might participate in mesangioproliferative glomerular dis-
ease came from the observation that macrophage-derived IL-i
could stimulate rat mesangial cell proliferation in vitro [16]. This
finding stimulated much interest given that glomerular macro-
phage infiltration is a common feature of most forms of human
and experimental glomerulonephritis [17], and that macrophages
are a major source of IL-i. In addition, a possible autocrine role
for IL-i in mesangial cell growth was suggested by the finding that
mesangial cells synthesize IL-i in response to IL-i itself [18, 19].
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Table 2. IL-i stimulation of mesangial cells in vitro
Cell proliferation
Cytokine production (IL-i, IL-6, IL-8, MCP-1, PDGF)
Adhesion molecule expression (ICAM-1, VCAM-1)
MHC class-Il expression with IFN7
Matrix production
Neutral protease production
Eicosanoid synthesis
Oxygen radical production
Nitric oxide synthesis
Since those early reports appeared, IL-i has been shown to induce
a wide variety of responses in cultured mesangial cells (Table 2).
Other renal cell types respond to IL-i in vitro, including
glomerular endothelium, glomerular epithelial cells, tubular epi-
thelial cells, and fibroblasts. As an example, the addition of IL-i
to tubular epithelial cells results in cytokine production (TNFa,
IL-6, IL-8), adhesion molecule expression (ICAM-1, VCAM-1),
prostaglandin F2 synthesis, endothelin release, and inhibition of
water and sodium reabsorption [20—25]. In addition, many renal
cell types such as mesangial cells, resident glomerular macro-
phages, tubular epithelial cells, and fibroblasts also can synthesize
IL-i [18, 19, 26]. In summary, a large body of evidence indicates
that IL-i induces changes in different renal cell types in vitro
comparable with those observed in disease. Thus, the first crite-
rion for a role of IL-i in glomerulonephritis has been fulfilled.
IL-i production in glomerulonephritis. Since the first report of
glomerular production of biologically active IL-i in human gb-
merulonephritis [1], a number of other studies have identified
IL-i protein and mRNA within renal biopsies using immunohis-
tochemistry, in-situ hybridization, and reverse transcriptase-poly-
merase chain reaction (RT-PCR) [27—29]. Interleukin-i expres-
sion has been identified in infiltrating macrophages within
glomeruli and interstitium and in epithelial cells of Bowman's
capsule and tubules. Increased numbers of IL-lji cells were
found in active versus inactive lesions in ANCA-positive glomer-
ulonephritis [27]. In IgA nephritis, glomerular IL-ia cells cor-
related with mesangial hypercellularity; similarly, interstitial IL-
ia cells correlated with tubulointerstitial changes and
proteinuria [28].
Because of the difficulty of working with human tissue, most
studies of IL-i in glomerulonephritis have been conducted in
experimental disease models. Techniques of cell culture and
bioassay, immunohistochemistry, Northern blot analysis, RNase-
protection, and RT-PCR have been used to demonstrate IL-i
production during both the acute and progressive phases of
different experimental models of nephritis such as lupus nephritis,
puromycin aminonucleoside nephritis, tubulointerstitial nephritis,
anti-GBM glomerulonephritis, and immune-complex glomerulo-
nephritis [30—38]. In these studies, glomerular IL-i production
has been attributed to resident and infiltrating macrophages,
while in the interstitium, infiltrating mononuclear cells also have
been shown to produce IL-i. Thus, the second criterion for renal
IL-i production in disease is satisfied.
IL-i exacerbates experimental acute nephritis. Administration of
IL-i causes shock, acute-phase response, and hypotension. It is
therefore difficult to distinguish specific renal effects from sys-
temic effects. However, an alternative approach is the administra-
tion of low doses of IL-i, which do not produce systemic effects,
during experimental acute glomerulonephritis. Injection of hu-
man IL-iD increased glomerular neutrophil accumulation, gb-
merular thrombosis, and proteinuria in acute rat anti-GBM
glomerulonephritis [39]. Similarly, administration of IL-ip in
rabbit immune-complex nephritis increased glomerular leukocyte
accumulation and proteinuria while decreasing creatinine clear-
ance [38]. Thus, the third criterion for administration of IL-i
causing or augmenting renal injury has been demonstrated, at
least in the experimental setting.
Strategies for blocking IL-i action in vivo. The fourth criterion
for proving a role for IL-i in glomerulonephritis is specifically
blocking IL-i's action in vivo and simultaneously demonstrating
disease suppression. Three basic approaches can be used to thwart
the action of IL-i in vivo: (1) blocking production of mature
IL-i/3; (2) neutralizing bioactive IL-i, and (3) competing for
occupancy of IL-i receptors (Fig. 2). Targeting the ICE is an
attractive means of inhibiting secretion of mature IL-if3 by
monocytes/macrophages [8]. indeed, the absolute substrate spec-
ificity of ICE for prolL-i/3 will facilitate the development of highly
specific ICE antagonists, which ought not to interfere with other
serine proteases. However, blocking of ICE activity has yet to be
proven effective in studies of experimental inflammation. The
second approach, neutralizing bioactive IL-i, has been achieved
by administering either anti-IL-i antibodies or a soluble form of
the IL-iR itself [40]. The third approach, preventing IL-i binding
to its receptor, has been accomplished using antibodies that
recognize the IL-iR and by the use of the IL-ira, which competes
with IL-i for binding to the IL-iR [41]. Indeed, IL-ira treatment
has been particularly successful in suppressing a number of
experimental inflammatory diseases [42].
Future studies aimed at blocking IL-i action will include the
use of gene therapy, in which vector DNA is introduced into renal
cells in vivo. This maneuver is designed to direct the transfected
cells either to inhibit IL-i production by the synthesis of anti-
sense IL-i RNA, or to secrete IL-ira. The feasibility of the latter
approach already has been demonstrated in rabbit synoviocytes
[43]. However, much experimental study and development are still
required before such approaches can be applied to clinical
disease.
Uncertainty exists as to the importance of IL-i in the induction
of glomerular injury. Passive immunization of rats with anti-IL-ia
antibodies prior to the administration of nephrotoxic serum plus
lipopolysaccharide significantly reduced albuminuria, capillary
thrombi, and glomerular leukocyte infiltration [44]. Interestingly,
pre-immunization against IL-ia conferred no protection in this
model. In a separate study, administration of anti-IL-ia antibody
also failed to reduce proteinuria and glomerular neutrophil
infiltration in acute anti-GBM glomerubonephritis in the rat [45].
However, administration of the IL-ira failed to protect against
acute glomerular injury in this model; thus IL-ij3 likely was not
involved in this process. Similarly, IL-ira treatment of accelerated
anti-GBM glomerulonephritis in the rat also failed to modulate
proteinuria 24 hours after nephrotoxic serum injection [46]. In a
further study of accelerated anti-GBM gbomerubonephritis in the
rat, IL-ira treatment partially inhibited proteinuria and gbomer-
ular neutrophil accumulation when given in conjunction with a
subnephritogenic dose, but not higher doses, of nephrotoxic
serum [47]. Thus, the importance of IL-i in the induction of acute
gbomerular injury critically depends on the dose and timing of
anti-IL-i 4) Sokible
ProIL-i13
mature IL-i
ICE inhibitor IL-ira
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Fig. 2. Schematic diagram of blocking IL-i
action in viva Three approaches are: (1)
blocking release of mature IL-1f3 by inhibiting
the interleukin-i converting enzyme (ICE); (2)
neutralizing mature IL-1Ø (and cell surface IL-
in) via antibody or soluble IL-iR; and (3)
blocking IL-i access to cell surface IL-1R by
competition with the IL-ira.
anti-GBM antibody administration and the co-stimulatory effects
of lipopolysaccharide.
To assess the therapeutic potential of blocking IL-i's action in
retarding the development of glomerulonephritis, we treated a
model of severe crescentic glomerulonephritis with the IL-ira.
Accelerated anti-GBM disease in the rat is a well-characterized
model of crescentic glomerulonephritis that also features pulmo-
nary hemorrhage and granuloma formation. This model of Good-
pasture's syndrome [48, 49] very closely resembles the case
presented here. Human recombinant IL-ira or saline was admin-
istered to immunoglobulin-primed rats by constant subcutaneous
infusion by means of a mini-osmotic pump implanted on the day
prior to nephrotoxic serum injection (day 0); animals were killed
on day i4 [46]. Saline-treated animals developed severe protein-
uria and hematuria and a significant decline in creatinine clear-
ance. Although IL-ira infusion did not prevent glomerular injury
(as measured by changes in 24-hr proteinuria and hematuria), it
did reduce the severity of later glomerular injury as measured by
maintenance of normal renal function (P C 0.05 vs. saline-
treated). Treatment with IL-ira also markedly improved renal
histology: it prevented renal enlargement associated with gross
inflammation and edema, reduced glomerular hypercellularity,
virtually abrogated glomerular atrophy and crescent formation,
and substantially reduced or completely abrogated tubular atro-
phy and fibrosis [46]. In the lung, IL-ira treatment markedly
reduced the widespread leukocytic infiltration, fibrinogen deposi-
tion, and areas of aggressive focal destruction and granuloma
formation, which were evident in saline-treated animals.
Having demonstrated that blocking the action of IL-i pro-
foundly inhibited the development of anti-GBM disease in the rat,
we next tried to determine whether blocking the action of IL-i
could arrest or even reverse established disease. We treated
groups of animals with a constant infusion of IL-ira or saline from
day 7 after injection of nephrotoxic serum until they were
sacrificed on day 2i. In addition, one group of untreated animals
was sacrificed on day 7 as a benchmark for disease severity at the
start of IL-ira treatment [50]. On day 7 of anti-GBM disease,
animals exhibited moderate proteinuria, moderate to severe he-
maturia, and a reduction in creatinine clearance. Days 7 to 2i
witnessed a significant deterioration in the saline-treated animals,
which developed severe proteinuria and severe hematuria, while
creatinine clearance remained impaired. In contrast, IL-ira treat-
ment over days 7 to 2i prevented the increase in proteinuria,
resolved the hematuria, and led to a gradual recovery of creati-
nine clearance to normal (P C 0.05 vs. saline-treated). Treatment
with IL-ira also halted the deterioration in renal histology that
was evident in the saline-treated animals. For example, on day 7,
that is, prior to treatment, crescent formation was evident in 14.0
3.2% of glomeruli. In the saline-treated animals, this increased
to 58.5 4.9% of glomeruli by day 21; however, the IL-ira-
treated animals had only 25.0 4.0% crescentic glomeruli on day
2i (IL-ira vs. saline, P C 0.01). In addition, glomerular hypercel-
lularity, glomerular sclerosis, tubular atrophy, and tubular fibrosis
in the IL-ira-treated animals on day 2i were indistinguishable
from that present on day 7 of untreated disease, and were
significantly less severe compared with saline-treated animals on
day 2i. Thus, the fourth criterion for proving a role for IL-i in
glomerulonephritis has been satisfied by the demonstration that
IL-ira treatment can both prevent the development of anti-GBM
disease and halt the progression of established disease in rats.
This is a particularly impressive result given the severity of the
disease in this model.
Mechanisms
After a pathogenetic role for IL-i in experimental glomerulo-
nephritis was established, the next issue was to identify the specific
mechanisms by which IL-i participates in the induction and
progression of renal injury. Given the many responses that IL-i
induces—both direct and indirect—in different renal cell types,
there is much to consider in terms of IL-i's action in disease. Let
us examine information gleaned from blocking the action of IL-i
in accelerated anti-GBM disease in rats in regard to: (1) leukocyte
infiltration and activation, (2) leukocyte adhesion molecule ex-
pression, (3) cell proliferation, (4) cytokine production, and (5)
the humoral immune response.
Leukocyte infiltration. T-cells and macrophages play a crucial
role in the induction and progression of anti-GBM disease in rats
and other experimental models of glomerulonephritis [17, 48, 49,
51—63]. Glomerular macrophages are associated with glomerular
hypercellularity and crescent formation; in the interstitium, focal
aggressive accumulation of activated T-cells (IL-2R+) and mac-
rophages is associated with tubular atrophy, Bowman's capsule
rupture, and granuloma formation. Mononuclear cells also stim-
ulate glomerulosclerosis and interstitial fibrosis. Treatment with
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IL-ira of anti-GBM disease in rats over days 0 to 14 resulted in a
50% reduction in glomerular macrophage accumulation. This
result is consistent with the partial reduction in glomerular injury
(proteinuria) observed. IL-ira treatment almost completely abro-
gated interstitial macrophage infiltration, again consistent with
the dramatic reduction in tubulointerstitial lesions and the pre-
vention of renal function impairment [46]. An interesting obser-
vation was that IL-ira treatment failed to significantly reduce
interstitial T-cell accumulation, however; T-cell activation (IL-2R
expression) was completely inhibited. This finding indicates that
different mechanisms are involved in the recruitment of T-cells
and macrophages into the interstitium, but that T-cell activation—
presumably through interaction with local antigen presenting
cells—was IL-i dependent. A co-stimulator of T-cell activation,
IL-i also can operate indirectly by upregulating the expression of
other co-stimulatory molecules such as ICAM-1, VCAJvI-1, and
MHC class II [64, 65]. In addition, the marked increase in T-cell
and macrophage accumulation and T-cell activation during the
progressive phase of disease (days 7 to 21) was completely halted
by IL-ira treatment over this period [50].
Adhesion molecule expression. Recent studies have demon-
strated that specific leukocyte adhesion molecules, particularly
ICAM-1 (CD54) and its ligands CD11a/CD18 and CD11b/CD18,
play a key role in facilitating leukocyte infiltration into the kidney
during the induction and progression of experimental glomerulo-
nephritis [45, 66—69]. The induction of anti-GBM disease in the
rat is followed by marked upregulation of endothelial ICAM-1
expression in both kidney and lung. Using immunoelectron mi-
croscopy, we noted ICAM-i and CD1 la expression at points of
adhesion between mononuclear cells and activated endothelium
in the glomerulus, interstitium, and lung during induction of the
disease [70—72]. In the later stages of disease, upregulation of
tubular ICAM-1 expression is patchy and associated with focal
leukocyte accumulation and tubular damage. Interestingly, the
adhesion of CD11a+ macrophages to the luminal surface of
ICAM-1+ tubules, together with the presence of CD11a+ mac-
rophages within ICAM-1 + tubules, suggests that macrophage-
mediated tubulitis in part might result from glomerular damage,
enabling infiltrating leukocytes to enter Bowman's space and then
migrate down the tubular lumen until binding to ICAM-1 +
segments [63].
During the induction of anti-GBM disease in rats (days 0 to 14),
the administration of IL-ira significantly reduced the intensity of
glomerular 1CAM-1 expression and partially reduced the number
of ICAM-1 + cells within the glomerulus [73]. This finding is
consistent with ICAM-1 being an IL-i-inducible molecule and
with the partial reduction in glomerular macrophage accumula-
tion observed. However, IL-ira treatment most profoundly inhib-
ited ICAM-1 expression in the interstitium. The intensity of
peritubular capillary ICAM-1 expression was reduced, and both
the intensity and number of cortical tubules expressing ICAM-1
(58.5 t 6.0 vs. 29.6 4.4% ICAM-i + tubules in saline- vs. IL-ira
treated; P < 0.001; normal is 9.3 1.6% ICATvI-1+ tubules)
markedly declined; this result was associated with the virtual
abrogation of interstitial macrophage accumulation and tubuloin-
terstitial damage [73]. These results also indicate that interstitial
T-cell accumulation in this model either was able to operate even
with the reduced level of ICAM-i expression, or it occurred
through an ICAM-i-independent mechanism.
Cell proliferation. Traditionally, it has been thought that after
monocytes leave the bone marrow, they have little or no potential
for cell proliferation, even when they enter tissues and differen-
tiate to become resident macrophages or enter tissues during
acute and chronic inflammatory conditions [74—77]. However, our
recent studies using a newly developed method of double immu-
nohistochemistry staining of ED1 + macrophages, together with
the proliferating cell nuclear antigen (PCNA) or incorporated
bromodeoxyuridine, have identified high levels of local macro-
phage proliferation in the kidney and lung (up to 60% of ED1+
cells) from day 7 onwards in anti-GBM disease in rats [78, 79].
This dramatic macrophage proliferation appears to be an index of
the severity of the tissue injury; we also observed high levels of
macrophage proliferation in a rat model of acute renal allograft
rejection [80], but far lower levels of macrophage proliferation
were evident in experimental nephrotic syndrome and experimen-
tal immune-complex glomerulonephritis [81, 82]. In anti-GBM
disease, PCNA+ macrophages were prominent in areas of severe
glomerular injury, crescent formation, tubulointerstitial damage,
and granuloma formation. Thus these macrophages probably play
an important role in progressive tissue thjury. Indeed, this might
be an important mechanism regulating the severity of the local
inflammatory response. Interestingly, macrophage proliferation
was approximately sixfold greater than was T-cell proliferation in
these tissues. The marked reduction in glomerular and interstitial
macrophage accumulation seen in IL-ira treatment of rat anti-
GBM disease might result in part from an inhibition of local
macrophage proliferation, although this has yet to be evaluated in
detail. Although no evidence suggests that IL-i itself induces
macrophage proliferation, IL-i is known to induce expression of
macrophage growth factors such as M-CSF [83].
Mesangial cell proliferation leading to hypercellularity and
eventual glomeruloscierosis is closely associated with glomerular
macrophage infiltration [59, 84]. Many studies have shown that
IL-i stimulates mesangial cell growth in vitro [16, 18, 85], but the
importance of IL-i in mesangial proliferation in vivo is unknown.
in rats with anti-GBM disease, IL-ira treatment during both the
developmental (days 0 to i4) and progressive (days 7 to 21) phases
significantly suppressed glomerular hypercellularity. This reduc-
tion in hypercellularity was due in part to a direct inhibition of
glomerular cell proliferation, as demonstrated by a 50% reduction
in glomerular PCNA+ cells (12.8 1.2 vs. 5.8 0.6 PCNA+
cells/glomerular cross section in saline vs. IL-ira on day 21; P <
0.001) [50]. Further analysis is necessary to distinguish between
the effect of iL-ira treatment on mesangial proliferation and
glomerular macrophage proliferation.
Another prominent feature of anti-GBM disease in rats is focal
tubular cell proliferation in areas of tubular injury associated with
local leukocyte accumulation. The regeneration of functional
tubules is presumably a response to injury similar to that seen
following acute ischemic injury [86]. Although the role of leuko-
cytes in tubular regeneration is unclear, they could potentially
provide tubular growth factors such as EGF and TGFr. Admin-
istration of iL-ira markedly reduced tubular proliferation, reflect-
ing the degree to which blocking the action of IL-i prevented
tubular cell damage.
Cytokine production. In-vitro studies have found that many
cytokines share overlapping functions and have led to the sugges-
tion of functional redundancy of the cytokine network in vivo. In
particular, IL-i and TNFa share many inflammatory actions in
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vitro [3]. Given this overlap, blocking just one cytokine was
expected to have only a modest effect on inflammatory processes
in vivo. However, studies using specific inhibitors of either IL-i or
TNFa have demonstrated profound suppressive effects in exper-
imental glomerulonephritis and other models of inflammatory
disease [3, 42, 45, 87, 88]. These studies show that little redun-
dancy exists in the cytokine network in vivo. Thus blocking the
action of a single cytokine in a disease model is an ideal setting in
which to examine the interrelationships between one specific
cytokine and the other cytokines and growth factors known to be
involved in different aspects of the disease process. Our current
studies focus on how blocking IL-i's action affects the production
of cytokines and growth factors such as TNFa, PDGF, and TGFI3
in experimental glomerulonephritis. This information is necessary
for the design of new therapeutic regimens. Experimental studies
have raised the expectation that blocking IL-i will be of thera-
peutic benefit in crescentic glomerulonephritis, but perhaps a
second agent will be necessary to block a different cytokine/growth
factor unaffected by IL-i blockade.
The humoral immune response. One further mechanism by
which blocking the action of IL-i could inhibit anti-GBM disease
in rats is modulation of the humoral immune response. In this
model, there is a strong systemic immune response to immunizing
rabbit IgG and subsequent challenge with rabbit nephrotoxic
serum [89]. Following injection of rabbit nephrotoxic serum,
rabbit IgG rapidly deposits on the glomerular and alveolar
basement membranes in a linear pattern, followed by deposition
of rat IgG and C3. Immunofluorescence staining found that
IL-ira treatment did not affect the deposition of immune reac-
tants in the kidney or lung [46]. Quantitation of serum levels of rat
anti-rabbit immunoglobulin antibody found no difference between
saline- and IL-ira-treated animals. Thus, blocking IL-i did not
affect the systemic humoral immune response. Indeed, a mild
antibody response to the administered human IL-ira was detected
in the serum of treated animals.
Future directions
The goal of research in experimental glomerulonephritis is to
understand the pathogenetic mechanisms of the disease and to
utilize this knowledge to prevent or treat the disease in humans.
Thus, the end result of the many studies that have identified a key
role for IL-i in glomerulonephritis is the development of a means
of blocking the production/action of IL-i in human disease. From
this viewpoint, the IL-ira is an attractive therapeutic drug be-
cause: (1) it can halt the progression of established disease in an
experimental model mimicking rapidly progressive glomerulone-
phritis; (2) the IL-ira is a naturally occurring specific inhibitor of
IL-i action; (3) clinical trials of septic shock and arthritis patients
have shown that high doses of IL-ira are tolerated extremely well
(Carmichael DF, personal communication), and (4) repeat
courses of IL-ira treatment appear feasible since the human
recombinant IL-ira is not expected to induce an antibody re-
sponse in patients. Therefore, the use of IL-ira in combination
with current immunosuppressive treatment would seem to be a
logical step in developing a clinical trial in patients with rapidly
progressive glomerulonephritis. We are currently setting up such
a prospective multicenter study. In summary, effective IL-i block-
ade holds promise for the future management of severe, rapidly
progressive crescentic glomerulonephritis, a disease that still has a
poor prognosis.
Questions and answers
DR. NIcoL.kos E. MnIAs (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): Are there any
circumstances in which IL-ira has been shown to exert agonistic
activities?
PROF. ATKINS: I am unaware of any circumstances in which the
IL-ira can trigger signaling of IL-i receptors. However, it is
possible to confer agonist activity to the IL-ira by a single amino
acid substitution of Lys-i45 to Asp [90].
DR. AsnIsH GUPTA (Senior Research Fellow, Department of
Experimental Medicine and Biotechnology, Postgraduate Institute of
Medical Education and Research, Chandigarh, India): What is the
relationship between IL-1f3 and IL-ira gene expression, and does
overexpression of IL-if3 downregulate IL-ira production? Also,
what is the status of the IL-ira gene expression of glomeruli from
treated or untreated rats?
PROF. ATKINS: Following stimulation by endotoxin, for example,
IL-iD is produced by macrophages and other cells within 2 to 4
hours. Production peaks at around i2 hours and is then down-
regulated. In contrast, IL-ira production is delayed until around
12 hours but remains elevated for 24 to 48 hours. Importantly, its
production is always in a large molar excess over that of IL-iD
production. In sepsis, where we see marked IL-113 overexpression,
there is also a dramatic increase in IL-ira expression, but the
kinetics of production of the two molecules follow the normal
pattern, in a recent study from Andrew Rees's group [91], no
IL-ip or IL-ira mRNA expression was detected in normal rat
glomeruli by Northern blot analysis or in-situ hybridization.
Following induction of anti-GBM glomerulonephritis, there was a
rapid induction of glomerular IL-1j3 mRNA, which was then
downregulated. Maximal glomerular production of IL-ira mRNA
was maintained as IL-i3 mRNA production fell.
PROF. S. C. DASH (All India Institute of Medical Sciences, New
Delh4 India): In light of the elegant studies you have presented,
would you like to postulate at what stage of the disease you see the
changes you demonstrated? Also, will it be practicable to treat the
patients, as I presume these changes occur very early, probably
before patients typically seek medical attention? Second, do you
think treatment by ICE inhibitors and IL-ira will be superior to
conventional immunosuppressants, as the latter are known to
reduce IL-i?
PROF. ATKINs: You raise an important issue in terms of early
treatment of patients with rapidly progressive disease. In the rat
model, we induce a severe insult concomitantly in all glomeruli,
and rapid disease progression follows. This model is somewhat
difficult to directly compare with human disease, because in the
latter we see varying degrees of injury in different glomeruli.
However, the ability of IL-ira treatment to halt disease progres-
sion in experimental animals with up to 14% crescents suggests
that this agent might well be beneficial for patients diagnosed
early. Second, conventional immunosuppressive drugs can reduce
IL-i levels, but only in a dose-dependent fashion. Doses of
methylprednisolone necessary to inhibit allograft rejection in rat
strain combinations only modestly reduce IL-i production within
the graft [92]. While we need more information on what happens
in human disease, we anticipate that specific inhibitors of ICE or
IL-ira treament will benefit patients receiving immunosuppres-
sive therapy, eliminating the remaining IL-i activity within the
kidney.
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DR. GIRISH NARAYEN (Professor of Nephrology, Osmania Medi-
cal College, Hyderabad, India): Does the level of IL-i correlate
with the type of crescentic glomerulonephritis, that is, anti-GBM,
immune-complex, or pauci-imniune disease?
PROF. ATKINS: Of the 3 patients in our original study, one had
vasculitis, one had anti-GBM disease, and the other had no
immune deposits. This is too small a sample from which to draw
conclusions regarding IL-i levels and the type of disease, how-
ever. We currently are performing an analysis of serum and urine
IL-i levels in a much larger group of patients with crescentic
glomerulonephritis.
DR. MADIAs: Is there evidence of increased expression of IL-i
in nonproliferative glomerular diseases as compared with normal
glomeruli?
PROF. ATKINS: In a study of human IgA disease, IL-la-positive
cells were detected in glomeruli in nonproliferative disease, but
there was a marked increase in the number of glomerular
IL-la-positive cells in proliferative disease [28]. Studies of IL-i
production in animal models all have utilized proliferative dis-
eases. There appears to be a large quantitative difference in
glomerular IL-i production between proliferative and nonprolif-
erative disease, but a role for IL-i in nonproliferative glomerulo-
nephritis is not excluded.
DR. B.V.R. MURTHY (Professor and Head, Department of Ne-
phrology, Nizam's Institute of Medical Sciences, Hyderabad, India):
Does IL-ira treatment of your anti-GBM disease model cause a
reduction in lung hemorrhage?
PROF. ATKINS: In a preliminary analysis, IL-ira treatment of rat
anti-GBM disease reduced macroscopic and microscopic pulmo-
nary injury and suppressed leukocyte infiltration and activation. A
detailed analysis of the effect of IL-ira is underway.
DR. J. STEWART CAMERON (Proftssor of Renal Medicine, UMDS,
Guy's Hospital, London, UK): Clearly a hierarchy exists among
the 20 or so cytokines now considered putative mediators of
injury, and 3 or 4 emerge as prime movers: IL-2, TGF/3, TNFa
and, as you have beautifully shown, IL-i. I think most of us were
surprised, and pleased, to see how much improvement you
obtained in your model. I note that in most parameters there was
improvement back towards normal, but not totally so. Given that
others have shown similar results by blocking TNFa in animal
models [87], have you considered blocking IL-i and TNFa in
combination? Also, to return to Dr. Dash's question, have you
examined whether IL-ira therapy improves the outcome in meth-
ylprednisolone-treated animals?
PROF. ATKINS: We have found that blocking TNFa with a
soluble form of the receptor is effective in our anti-GBM disease
model, and shortly we will start a study to examine whether
blocking IL-i and TNFa gives any added benefit above that
obtained by blocking either cytokine alone. We also have a project
on the drawing board to determine whether blocking IL-i action
can provide any additional benefit to conventional immunosup-
pressive treatment of the anti-GBM disease model.
DR. JOHN T. HARRINGTON (Dean for Academic Affairs, Tufts
University School of Medicine, Boston, Massachusetts): Do you
know of any studies of experimental glomerulonephritis in which
anti-ICAM-1 infusion has been compared to IL-ira infusion? Are
there any synergistic effects?
PROF. ATKINS: I am not aware of any study combining strategies
of blocking ICAM-1 and IL-i. However, we would predict some
synergistic effects, as anti-ICAM-1 antibody is more effective in
blocking the initiation of glomerular leukocyte infiltration than
IL-ira treatment, although both appear equally good at inhibiting
leukocyte-mediated interstitial damage. It would be an interesting
experiment.
DR. Mumiu JAYARAMAN (Professor of Nephrology, Kilpauk Med-
ical College, Madras, India): Most patients with anti-GBM cres-
centic glomerulonephritis respond to steroids, cyclophosphamide,
and plasmapheresis. That therapy was employed in this patient,
yet she died. What factors were implicated in the failure of
therapy in this patient? Would infusion of IL-ira have helped this
patient?
PROF. ATKINS: She died because we could not ventilate her due
to severe lung hemorrhage. We treated her immediately on
clinical suspicion with plasmapheresis, prednisolone, and cyclo-
phosphamide in maximum doses, and controlled her renal failure.
We did not use anti-coagulation therapy because of the plasma-
pheresis. I believe that she died of overwhelming irreversible
hypoxia.
DR. CAMERON: I have a comment. One other experimental
treatment for severe pulmonary hemorrhage is temporary support
by long-term extracorporeal membrane oxygenation (ECMO),
developed by Gattinoni in Milan [93]. Anecdotal reports of
successful results of this treatment in patients with pulmonary
hemorrhage arising from immune disorders are circulating, but
patients whose lungs are irreversibly damaged will not be helped
even by this aggressive therapy.
DR. BRAT Si-iii (Consultant Nephrologist, Hinduja Hospita4
Bombay, India): Have you looked at IL-i activity in inflammatory
glomerular diseases without crescent formation? In that case,
what determines crescent formation? Is it the amount of IL-i
production?
PROF. ATKINS: We have demonstrated IL-i production in a rat
model of focal segmental glomerulosclerosis that does not feature
crescent formation [31]. Indeed, IL-i production has been docu-
mented in a number of disease models that do not involve
crescent formation. Therefore, it appears that the amount of IL-i
production in disease is related primarily to the severity of the
disease process rather than to crescent formation specifically.
DR. THOMAS MArrHEW (Professor of Nephrology, Calicut, India):
Can you determine the severity of rapidly progressive glomerulo-
nephritis by quantitating the level of interleukin-1 in blood?
PROF. ATKINS: We are currently engaged in a fairly large study
of IL-i levels in serum and urine in human glomerulonephritis to
try and address that and other questions.
DR. MADIAs: Does IL-i cause an increase in glomerular and
interstitial matrix in models of renal disease?
PROF. ATKINS: We found that IL-ira treatment of rat anti-GBM
disease caused a reduction of matrix deposition. While this is
consistent with in-vitro studies demonstrating that IL-i increases
matrix synthesis, it does not exclude the possibility that IL-i acts
indirectly in-vivo to induce production of other pro-sclerotic
factors such as FGF and TGF/3. This issue remains to be resolved.
DR. ANIL Gm (Consultant Nephrologist, Muijibhai Patel Uro-
logical Hospital, Nadiad, India): Do you have any data on renal
function and histology in the rat model after cessation of a 14-day
period of IL-ira treatment?
PROF. ATKINS: As yet, we have not examined whether the
disease progresses or remains suppressed after IL-ira treatment is
stopped. Given that these animals maintain a vigorous response to
rabbit IgG, and that there is still strong rabbit IgG deposition on
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the GBM, we would predict that the disease would progress after
cessation of treatment, but at a reduced rate.
MAJOR U. K. Sa&iuvi.& (Nephrologist, Command Hospital, East-
ern Comman4 Calcutta, India): Does the expression of IL-1p and
IL-ira differ, with more damage occurring proportionate to a
relative increase in IL-if3 production versus IL-ira production? If
so, would an endogenous increase in IL-ira expression be the
ultimate aim of therapeutic intervention in glomerulonephritis?
PROF. ATKINS: While we know that there is a fairly consistent
relationship between IL-i/3 and IL-ira production when mea-
sured in terms of mRNA or protein in blood cells and serum and
in in-vitro studies, we still know little of the relative activity of the
two molecules in the tissue microenvironments in which they act.
Upregulation of endogenous IL-ira production is an attractive
idea, but it is unlikely that this gene could be induced without
affecting production of other molecules. Therefore, administra-
tion of recombinant IL-ira or attempts to transfect cells with
plasmids driving IL-ira production remain the most attractive
therapeutic options.
DR. VIFUL C. CHITALIA (Nephrology Resident, KEM Hospital,
Bombay, India): Can you correlate the mechanism of action of
IL-i in glomerulonephritis with acute transplant rejection? If so,
could we use IL-ira to treat transplant rejection?
PROF. ATKINS: It is well described that IL-i is produced during
experimental and human acute allograft rejection, but little
information exists regarding the role of IL-i in this process.
However, the ability of IL-ira to suppress graft-versus-host dis-
ease does suggest that IL-ira could be of benefit as an adjunct to
conventional therapy in the treatment of acute allograft rejection.
DR. SANJAY JAIN (Assistant Professor, Department of Internal
Medicine, Postgraduate Institute of Medical Education and Re-
search, Chandigarh): What is the fundamental function of IL-la?
PROF. ATKINS: This is a rather controversial topic. Most IL-la
remains within the macrophage in the precursor form. However,
pro-IL-ia on the cell surface can trigger IL-i receptors on an
adjacent cell, and it therefore could have a local paracrine role.
Most investigators believe that most IL-ia in the circulation is
released from damaged cells and therefore reflects the degree of
cellular injury. It is a difficult question. We will need the devel-
opment of an IL-la knock-out mouse to define the precise roles
of IL-ia in various inflammatory and immune responses.
DR. JAIN: Can you block the efflux of IL-i13 from the cytoplasm?
Would that have any therapeutic potential?
PROF. ATKINS: The secretion of IL-1j3 is intimately linked with
the action of the cell-surface-associated interleukin-if3 converting
enzyme (ICE). Therefore, it would be necessary to target ICE in
order to prevent IL-i/3 release from the cytoplasm. Even then, it
is unclear whether this would block effiux or simply result in
secretion of the inactive pro-IL-l/3 form of the molecule.
DR. HARRINGTON: If you were to conduct a clinical trial of the
efficacy of IL-ira, what type of patients would you include, and
what trial design would you employ?
PROF. ATKINS: We are indeed setting up such a trial as an
international multicenter, randomized, prospective and blinded
study, using IL-ira as an adjunct to a standardized conventional
immunosuppressive regimen (prednisolone and cyclophospha-
mide) in patients with rapidly progressive glomerulonephritis. The
majority of these patients would have a systemic vasculitis as the
cause of their disease, although other subgroups such as anti-
GBM disease would be included as well.
DR. JM PRAKASH (Reader in Nephrology, Institute of Medical
Sciences, Banaras, Hindu University, Varanasi, India): Is IL-i
produced by normal kidney? If so, what is its role in health? Also,
what is the role of IL-i in glomerular diseases other than
crescentic glomerulonephritis?
PROF. ATKINS: It is somewhat controversial as to whether IL-i is
produced within the normal kidney. Most, but not all, Northern
blot studies have failed to detect IL-ia or IL-i /3 mRNA in kidney.
Similarly, varied results have been obtained with the very sensitive
reverse transcription PCR technique.
DR. THOMAS HOSTETFER (Director, Division of Renal Diseases
and Hypertension, University of Minnesota Medical School, Minne-
apolis, Minnesota): Is the level of IL-ira expression prognostic of
the outcome in experimental studies, and can IL-ira production
be stimulated?
PROF. A1IUN5: Very little has been done in terms of measuring
IL-ira production in experimental disease models beyond mRNA
expression. It is too early to say whether IL-ira production has
prognostic significance. Second, I believe that factors used thus far
to upregulate Il-ira expression also induce IL-i expression.
DR. DAYANATH MI5HR.k (Resident, Institute of Kidney Diseases
and Research, Ahmedabad, India): How did IL-ira treatment
affect the level of other interleukins in the experimental model?
Also, given the marked decrease in IL-2R expression in the
treated animals, do you think that anti-IL-2R antibodies would
have salutary effects in this model?
PROF. ATKINs: It is important that we determine the effect of
blocking IL-i action on the production of other cytokines and
growth factors in the disease process. Not only will this help us a
great deal in understanding the interrelationships between the
different cytokines and growth factors in vivo, but it will identify
any factor that is unaffected by IL-l blockade and which should be
considered for specific inhibition in conjunction with IL-ira
treatment. These studies are underway in our laboratory. In
regard to the second question, I believe that anti-IL-2R antibodies
will suppress the disease process, particularly in view of their
effectiveness in inhibiting graft rejection.
DR. ALEX M. DAvISON (Consultant Renal Physician, St. James's
University Hospita4 Leeds, UK): A study by the U.K. Glomeru-
lonephritis Registry found that the majority of patients with
anti-GBM nephritis presented in late spring, that is, April to June
[94]. This was confirmed by Savage et al [95], who reported a
seasonal variation in the positive results of anti-GBM testing. Do
you find a seasonal incidence in Australia and, if so, is it October
to December?
PROF. AriciNs: We haven't performed a systematic analysis of
the presentation of anti-GEM glomerulonephritis in Australia, so
I cannot offer a definitive answer. My impression is that there is an
increased winter incidence.
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